Pfizer – Optimizing Venous Thromboembolism Management in Latin America – Request for Proposals
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire within your unit
Memorial Deadline: Tuesday 31st, August 2021
External Deadline: Friday 3rd, September 2021
Description
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMGcompetitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review processto make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP.
For all independent quality improvementgrants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on:
- * Improving detection, case finding, diagnosis and treatment optimization of Venous Thromboembolism (VTE).
- * Standardization of VTE diagnosis and treatment according to anticoagulation guidelines.
- * Thrombosis risk assessment and VTE treatment optimization according to patient characteristic (age, comorbidities, obesity, low weight, Cancer associated VTE, etc.) according to anticoagulation guidelines.
- * Improving VTE recurrence awareness to optimize transition of care from the inpatient to the outpatient settings.
- * Improving patient education to optimize treatment adherence and engagement in decision making.
Additional information can be found here.